Premium
IC‐P‐127: Multicenter quantitative amyloid PET imaging in phase III alzheimer therapeutic trials: Strategies for achieving good imaging practices in the support of drug development
Author(s) -
Seibyl John P.,
Zubal George,
Tamagnan Gilles,
Marek Kenneth
Publication year - 2009
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2009.05.099
Subject(s) - clinical trial , drug development , medicine , medical physics , standardization , neuroimaging , nuclear medicine , computer science , pathology , drug , pharmacology , psychiatry , operating system
different sites were initially reconstructed using the sites’ routine methods. The methods used were FBP and OSEM. The co-registered PET data sets underwent VOI analysis to obtain putamen cavity to refernce ratios. The returned VOI capture ratios had a mean of 1.3 to 1 with a SD of 0.06 (less than 10% total difference). With optimisation of post reconstruction filtering, these differences reduce further. Conclusions: Partial volume effects reduce the measured uptake ratios as expected. However, on the cameras and reconstruction methods used there is good consistency between the ratios. The level of variation in uptake ratio introduced by measurements accross different cameras is small compared to the actual variation in uptake found in both amyloid negative and positive images. This supports the robustness of quantitative measurements via VOI analysis. Striatal phantom images and target/reference ratios.